Shares of Eurofins Scient (OTCMKTS:ERFSF - Get Free Report) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $58.20 and traded as high as $71.85. Eurofins Scient shares last traded at $71.53, with a volume of 715 shares traded.
Analysts Set New Price Targets
A number of research analysts have commented on the company. HSBC lowered Eurofins Scient to a "hold" rating in a research report on Friday, April 25th. Hsbc Global Res lowered Eurofins Scient from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Five research analysts have rated the stock with a hold rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold".
Get Our Latest Stock Analysis on ERFSF
Eurofins Scient Stock Performance
The company has a debt-to-equity ratio of 0.58, a current ratio of 1.16 and a quick ratio of 1.09. The firm's 50 day moving average price is $67.36 and its 200-day moving average price is $58.20.
About Eurofins Scient
(
Get Free Report)
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of various analytical methods and tests to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products.
Further Reading
Before you consider Eurofins Scient, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eurofins Scient wasn't on the list.
While Eurofins Scient currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
